TELA · TELA Bio, Inc.
$0.64
-0.03 (-4.97%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 11, 2026
Market Cap
$28.93M
Shares
44.89M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.64
Open$0.68
Day$0.63–0.70
52W close$0.56–1.83
Avg vol 30d118K
Short int341K · 0.8% float · 10.5d
Short vol51%
Last earningsAug 10, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−18%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
7%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−16%
trailing
YTD return
−45%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.76% of float · ▼ -5.6% MoM · 10.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
45 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
68%
expanding
EPS growth
+38%
Y/Y
Free cash flow
$-28.7M
Balance sheet
$4.8M
net debt
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
15.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 12, 2026
Revenue growth
· Full year 2026
at least 8%
Prior guidance
period ended
· from the 8-K filed Mar 24, 2026
First quarter 2026 revenue
· First quarter 2026
$18.5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.76% of float · ▼ -5.6% MoM · 10.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
45 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 7%
Range high $2
vs 200-day avg -29%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| hernia unit volume growth | 12% | the second quarter of 2026 | — |
| international revenue growth | 26% | the second quarter of 2026 | — |
| LiquiFix revenue growth | 39% | the second quarter of 2026 | — |
| OviTex unit volume growth | 12% | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TELA
this stock
TELA Bio, Inc.
|
$28.93M | -45.4% | +15.8% | — | 0.8% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TELA | -25.9% | -11.9% | -15.9% | -11.7% | -45.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -26.3% | -16.3% | -29.7% | -15.7% | -59.3% |
Key facts
CIK
1561921
CUSIP
872381108
13F (30d)
46 filings
44 filers
Visit website
Investor relations